Replies to post #7978 on Halozyme Therapeutics Inc (HALO)

[Fred Kadiddlehopper]

Management has not given us many reasons to cheer, so I doubt it.

[biotechinvestor1]

I have been a shareholder since 2011. My posts over a decade on this and other boards reflect this and have been pretty consistent.

I’ve done well with this investment over this time period. However, I am of the opinion that management did not execute as promised in 2023 (eg, only delivered one of the 3 deals promised).

Halo is severely undervalued. With a phat profit margin and top 32 growth stocks at great value (per Morgan Stanely last week), halo is still trading at a 2023 PE ratio of 14 and 2024 PE ratio PE ratio of 10 (see link below). This way below peers in biotech and healthcare sector.

https://www.nasdaq.com/market-activity/stocks/halo/price-earnings-peg-ratios

New management will be able to unlock the enormous value in Halo.